Search U.S. Product Recalls Database

Showing 1261–1280 of 1571 results

Sort:

Amlodipine Valsartan Tablets (Aurobindo) – NDEA Impurity (2018)

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Class IIModerate

FDADec 31, 2018Nationwide• Aurobindo Pharma USA Inc.

Losartan Potassium Tablets (Torrent) – NDEA Impurity (2018)

Class IIModerate

FDA

Stay Informed

Search Product Recalls

Amlodipine Valsartan Tablets (Aurobindo) – NDEA Impurity (2018)

Losartan Potassium Tablets (Torrent) – NDEA Impurity (2018)

Losartan Potassium Tablets (Torrent) – NDEA Impurity (2018)

Losartan Potassium Tablets (Torrent) – NDEA Impurity (2018)

Losartan Hydrochlorothiazide Tablets (Torrent) – NDEA Impurity (2018)

Losartan Hydrochlorothiazide Tablets (Torrent) – NDEA Impurity (2018)

Amlodipine & Valsartan (Mylan) – NDEA Contamination (2018)

Valsartan/Hydrochlorothiazide Tablets (Mylan) – impurity detected (2018)

Valsartan (Mylan) – NDEA Contamination (2018)

Valsartan & Hydrochlorothiazide (Mylan) – NDEA Contamination (2018)

Valsartan (Mylan) – NDEA Contamination (2018)

Amlodipine & Valsartan (Mylan) – NDEA Contamination (2018)

Valsartan & Hydrochlorothiazide (Mylan) – NDEA Contamination (2018)

Valsartan (Mylan) – NDEA Contamination (2018)

Amlodipine & Valsartan (Mylan) – NDEA Contamination (2018)

Amlodipine & Valsartan (Mylan) – NDEA Contamination (2018)

Valsartan (Mylan) – NDEA Contamination (2018)

Valsartan & Hydrochlorothiazide (Mylan) – NDEA Contamination (2018)

Valsartan & Hydrochlorothiazide (Mylan) – NDEA Contamination (2018)

Amlodipine & Valsartan (Teva) – NDEA Contamination (2018)